Literature DB >> 19885783

The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment.

Bariş Türkbey1, David Thomasson, Yuxi Pang, Marcelino Bernardo, Peter L Choyke.   

Abstract

Angiogenesis is a key step in the pathophysiology of tumor growth and metastatic spread. Recently, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has emerged as a method for assessing angiogenesis both during the initial diagnosis and for follow up of anti-angiogenic therapies. In this review, we discuss the technical aspects of implementing DCE-MRI in clinical practice with emphasis on acquisition methods and analytic techniques.

Entities:  

Mesh：

Year:  2009        PMID： 19885783      PMCID： PMC3518910          DOI： 10.4261/1305-3825.DIR.2537-08.1

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN： 1305-3825            Impact factor:   2.630


  17 in total

1.  MRI of the uterus, uterine cervix, and vagina: diagnostic performance of dynamic contrast-enhanced fast multiplanar gradient-echo imaging in comparison with fast spin-echo T2-weighted pulse imaging.

Authors:  P F Liu; G P Krestin; R A Huch; S C Göhde; R F Caduff; J F Debatin
Journal:  Eur Radiol       Date:  1998       Impact factor: 5.315

2.  Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results.

Authors:  G J Jager; E T Ruijter; C A van de Kaa; J J de la Rosette; G O Oosterhof; J R Thornbury; S H Ruijs; J O Barentsz
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

3.  Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer.

Authors:  N A Mayr; W T Yuh; J C Arnholt; J C Ehrhardt; J I Sorosky; V A Magnotta; K S Berbaum; W Zhen; A C Paulino; L W Oberley; A K Sood; J M Buatti
Journal:  J Magn Reson Imaging       Date:  2000-12       Impact factor: 4.813

4.  Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging.

Authors:  J O Barentsz; O Berger-Hartog; J A Witjes; C Hulsbergen-van der Kaa; G O Oosterhof; J A VanderLaak; H Kondacki; S H Ruijs
Journal:  Radiology       Date:  1998-06       Impact factor: 11.105

5.  Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma.

Authors:  W E Reddick; J S Taylor; B D Fletcher
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

Review 6.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

7.  Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Carmel Hayes; Anwar R Padhani; Martin O Leach
Journal:  NMR Biomed       Date:  2002-04       Impact factor: 4.044

Review 8.  Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Peter L Choyke; Andrew J Dwyer; Michael V Knopp
Journal:  J Magn Reson Imaging       Date:  2003-05       Impact factor: 4.813

9.  Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience.

Authors:  Arpi Thukral; David M Thomasson; Catherine K Chow; Reyes Eulate; Suparna B Wedam; Sandeep N Gupta; Betty J Wise; Seth M Steinberg; David J Liewehr; Peter L Choyke; Sandra M Swain
Journal:  Radiology       Date:  2007-09       Impact factor: 11.105

Review 10.  Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Authors:  P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813
View more
  45 in total

1.  Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer.

Authors:  Daniel I Golden; Jafi A Lipson; Melinda L Telli; James M Ford; Daniel L Rubin
Journal:  J Am Med Inform Assoc       Date:  2013-06-19       Impact factor: 4.497

Review 2.  Tracer-kinetic modeling of dynamic contrast-enhanced MRI and CT: a primer.

Authors:  Michael Ingrisch; Steven Sourbron
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-04-06       Impact factor: 2.745

3.  Dynamics of rabbit brain edema in focal lesion and perilesion area after traumatic brain injury: a MRI study.

Authors:  Xiao-Er Wei; Yu-Zhen Zhang; Yue-Hua Li; Ming-Hua Li; Wen-Bin Li
Journal:  J Neurotrauma       Date:  2011-10-04       Impact factor: 5.269

4.  Dynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model.

Authors:  Wei Zhang; Hui Juan Chen; Zhen J Wang; Wei Huang; Long Jiang Zhang
Journal:  Eur Radiol       Date:  2016-08-03       Impact factor: 5.315

5.  Quantitative Analysis of DCE-MRI and RESOLVE-DWI for Differentiating Nasopharyngeal Carcinoma from Nasopharyngeal Lymphoid Hyperplasia.

Authors:  J Y Yu; D Zhang; X L Huang; J Ma; C Yang; X J Li; H Xiong; B Zhou; R K Liao; Z Y Tang
Journal:  J Med Syst       Date:  2020-02-26       Impact factor: 4.460

Review 6.  Imaging tumor hypoxia to advance radiation oncology.

Authors:  Chen-Ting Lee; Mary-Keara Boss; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

7.  Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up.

Authors:  Soroush Rais-Bahrami; Barış Türkbey; Ardeshir R Rastinehad; Annerleim Walton-Diaz; Anthony N Hoang; M Minhaj Siddiqui; Lambros Stamatakis; Hong Truong; Jeffrey W Nix; Srinivas Vourganti; Kinzya B Grant; Maria J Merino; Peter L Choyke; Peter A Pinto
Journal:  Diagn Interv Radiol       Date:  2014 Jul-Aug       Impact factor: 2.630

8.  Contrast-enhanced dynamic and diffusion-weighted magnetic resonance imaging at 3.0 T to assess early-stage nasopharyngeal carcinoma.

Authors:  Liangping Ni; Ying Liu
Journal:  Oncol Lett       Date:  2018-02-05       Impact factor: 2.967

9.  Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study.

Authors:  Dong Ho Lee; Se Hyung Kim; Seock-Ah Im; Do-Youn Oh; Tae-Yong Kim; Joon Koo Han
Journal:  Eur Radiol       Date:  2015-11-28       Impact factor: 5.315

10.  Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.

Authors:  Jung-Min Lee; Christina M Annunziata; John L Hays; Liang Cao; Peter Choyke; Minshu Yu; Daniel An; Ismail Baris Turkbey; Lori M Minasian; Seth M Steinberg; Helen Chen; John Wright; Elise C Kohn
Journal:  Gynecol Oncol       Date:  2020-08-01       Impact factor: 5.482
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.